It has been two decades since the unexpected link between maternal anti-SSA/Ro-SSB/La antibodies and congenital heart block (CHB) was reported. 1, 2 This extraordinary model of antibody-mediated tissue injury that targets a speci c organ at a speci c developmental stage has presented several challenges to understanding pathogenesis. The penetrance of disease expression is low 3 and the candidate antibodies recognize normally inaccessible intracellular antigens. 4 Furthermore, the fetal cardiac response to insult is remarkable in that irreversible damage to the conducting system can become clinically manifest in less than two weeks. 5 Fortunately, this rare disease has garnered attention fostering integration of clues from the bench and bedside. As more cases have been identi ed, it has become apparent that there is a spectrum of cardiac involvement. 6 The nal outcome, third-degree block, is the consequence of a cascade that we hypothesize starts with translocation of the antigens to the cell surface which, bound by circulating maternal antibodies, promotes a shift of macrophage clearance towards a state of hypersecretion of both proin ammatory and pro brotic cytokines. 7 These cytokines may contribute to myocardial dysfunction and eventuate in broblast transdifferentiation and, ultimately, brotic replacement of the atrioventricular (AV) node. 8 Inherent in this hypothesis is the notion that most fetuses exposed even to maternal autoantibodies with identical speci cities will not be affected at all. A minority will have only myocardial dysfunction or a clinically insigni cant block, and in rare cases the die is irreparably cast. Accordingly, we have proposed a triple hit: one contributed by the mother, the antibodies, which are necessary but not suf cient; one contributed by the fetus, which is likely to be a combination of genetic risk factors; and one contributed by the in utero environment.
The study of twins and triplets in anti-SSA/Ro-SSB/La antibody-exposed pregnancies in which there is variability in the expression of cardiac disease lends credibility to the 'cascade' hypothesis. These informative in vivo experiments of nature provide clues to the role of host factors in the enhancement or diminution of proin ammatory/ brosing effects mediated by maternal autoantibodies. In this issue of Lupus, Fesslova and colleagues report a fascinating situation in which the degree of heart block was discordant in a triplet gestation. 9 This case report affords a unique opportunity to gauge the effect of a speci c antibody pro le on disease phenotype. Regardless of whether the fetuses share a common placenta or not, it is likely that even if a mother had three types of antibodies (Type A causing CHB, Type B causing skin rashes, and Type C being nonpathogenic), the proportion of these antibodies should be similar in each fetal circulation. Types A and B by de nition must be of the correct isotype (i.e., IgG, subclasses 1 -4) to be transported across the trophoblast, while Type C might not be transported at all (IgM or IgA). One might consider quantitative differences in each fetus if there are separate placentas, but it is dif cult to envision a mechanism to explain why one placenta would transport antibodies more selectively than another unless Fc receptors were differentially expressed.
Of 19 dizygotic twin pairs 2,10-22 (Silverman D, Hospital for Sick Children, Toronto, Ontario, Personal Communication) and one additional set of triplets 23 published in addition to that of Fesslova et al., 12 sets were discordant 2,10 -16 (Silverman D, Personal Communication) and three concordant [17] [18] [19] for CHB, and three were discordant 12,20,21 and two concordant 22, 23 for cutaneous lesions. These data strongly support that the ne speci city of the maternal anti-SSA/Ro-SSB/La pro le, while necessary, is not suf cient for disease expression, and justify the search for fetal genetic factors.
In our laboratory, the hunt for genetic factors was driven by in vitro and in vivo observations demonstrating that cytokines generate and sustain in ammation and brosis, thus amplifying the pathologic effects of maternal autoantibodies in favor of cardiac scarring. 8, 24 Accordingly, an initial search for candidate genes included polymorphisms of the TNFa promoter region and codons 10 and 25 of the TGFb gene. These were evaluated in 88 children (40 CHB, 17 rash, 31 unaffected siblings) and 74 mothers from the Research Registry for Neonatal Lupus. 25 Signi cantly increased frequency of the -308A (high-producer) allele of TNFa was observed in all the Registry groups compared to controls. In contrast, the TGFb polymorphism Leu 10 (associated with increased brosis) was signi cantly higher in CHB children (genotypic frequency 60%, allelic frequency 78%) than unaffected offspring (genotypic frequency 29%, P 0.016; allelic frequency 56%, P 0.011) and controls, while there were no signi cant differences between controls and other Registry groups. For the TGFb polymorphism, Arg 25 , there were no signi cant differences between Registry groups and controls. These ndings suggest that TNFa may be one of several factors that amplify susceptibility; however, the genetic studies more convincingly link TGFb to the pathogenesis of CHB. This pro brosing cytokine and its secretion/activation circuitry may provide a novel direction for evaluating fetal factors in the development of a robust animal model of CHB as well as therapeutic strategies in humans.
The contribution of environmental factors would be most obvious in cases of discordant disease expression in monozygotic twins, since the placenta is shared and the fetal genetics are identical. Indeed, of seven monozygotic twin pairs published, 13, 17, [26] [27] [28] only one pair is concordant for CHB 17 and one for rash. 26 In four discordant pairs, one twin had CHB and the other was healthy. 13, 27 The seventh pair is an intriguing case, reported by Gawkrodger and Beveridge, of disparate disease expression in male twins who were in the same amniotic sac and shared a common placenta. 28 The mother had anti-SSA/Ro and anti-SSB/La antibodies. One infant presented at eight weeks of age with Stokes Adams attack and second-degree heart block, a facial rash and evidence of haemolytic anaemia, while his twin brother had merely a 'peeling' facial rash at 15 weeks of age.
While zygosity was an early and obvious consideration, investigators in the last decade have also addressed HLA identity between twins and mothers. Watson et al. performed HLA studies and C4 phenotypes on dizygotic twins discordant for isolated CHB. 14 Both infants had identical HLA (DR4, DR7) and C4 phenotypes (C4A3.QOB1.1). Serum from the mother and both cord bloods demonstrated anti-SSA/Ro and SSB/La antibodies with no signi cant difference in titre noted in the cord blood of either twin when compared with maternal titres. Brucato et al. reported another pair of HLA identical twins discordant for CHB, 15 and a third such pair was reported by Kaaja et al. 16 There are ve published cases of concordant NLS manifestations in twins: four CHB [17] [18] [19] and one rash. 26 Notably, in all three of these concordant cases for which HLA typing was done (two monozygotic, one dizygotic), the twins had the HLA-Cw3 allele. 17, 26 The spectrum of arrhythmias and, in particular, progression of disease associated with maternal anti-SSA/Ro-SSB/La antibodies is illustrated in the report by Fesslova et al., in which myocarditis progressed to complete block in one fetus, and rst-degree progressed to intermittent second-degree block in another of the triplets postpartum. 9 Progression was also observed in a recent review of records of all children enrolled in the Research Registry. 6 Of 187 children with CHB whose mothers have anti-SSA/Ro-SSB/La antibodies, nine had a prolonged PR interval on ECG at birth, four of whom progressed to more advanced AV block. A child whose younger sibling had third-degree block was diagnosed with rst-degree block at 10 years of age, at the time of surgery for a broken wrist. Two children diagnosed in utero with second-degree block were treated with dexamethasone and reverted to normal sinus rhythm by birth, but ultimately progressed to third-degree block. Four children had second-degree block at birth: of these, two progressed to third-degree block. Sinus bradycardia (< 100 bpm) was present in three (3.8%) of 78 fetuses for whom atrial rates were recorded by echocardiogram. Of 40 neonates for whom ECGs were available, the mean atrial rate was 137+ 20 bpm (range 75 -200). These data have important research and clinical implications. In contrast to the AV node, permanent sinoatrial nodal involvement was not clinically apparent in this cohort. Perhaps many fetuses sustain mild in ammation, but resolution is variable, as suggested by the presence of incomplete AV block. Since subsequent progression of lessadvanced degrees of block can occur, an ECG to rule out rst-degree block should be performed on all infants born to mothers with anti-SSA/Ro-SSB/La antibodies.
To more formally address whether cardiac injury progresses through stages, some of which might be reversible thereby preventing or forestalling brosis of the node and irreversible third-degree block, studies of large cohorts of patients are needed. Currently ongoing in the USA is an NIH-supported study to identify the earliest noninvasive echocardiographic marker of AV nodal dysfunction and/or myocardial injury. Simultaneous gated-pulsed Doppler studies of the atrioventricular and semilunar valves have been described in helping identify rhythm disturbances in fetal hearts. By using the gated-pulsed Doppler technique, time intervals from the onset of the mitral A wave (atrial systole) to the onset of the aortic pulsed Doppler tracing (ventricular systole) within the same left ventricular cardiac cycle may be measured. This time interval represents the 'mechanical' PR interval. Its validity was con rmed by neonatal electrocardiographic correlation to the pulsed Doppler mechanical PR interval. 29 The normal mechanical PR interval in the fetus is Ed itorial JP Buyon, A Rupel and RM Clancy 0.12+ 0.02s (95% con dence intervals 0.10-0.14). The measurement of mechanical PR interval of the fetal heart is being measured in a prospective evaluation of 100 pregnant women with anti-SSA/Ro-SSB/La antibodies. This will be accomplished by weekly echocardiograms from 16-26 weeks of gestation and every other week from 17 to 32 weeks.
The case report of Fesslova et al. also makes an important point about the ef cacy of intrauterine steroids. 9 One triplet showed signs of myocarditis prior to the development of complete block. Ascites improved with the institution of dexamethasone depite persistence of the block. A second of the triplets developed signs of myocarditis, and ECG at birth showed rst-degree block, which progressed to intermittent second-degree block within one month of age. Somewhat disappointingly, despite exposure to steroids, echocardiography at birth showed enlarged venticles, reduced left ventricular contractility, and moderate tricuspid and mitral regurgitation in both of these infants. This report further con rms that dexamethasone is not likely to reverse third-degree block. However, the potential for diminishing an in ammatory fetal response remains plausible. Saleeb et al. reported on a retrospective review of the data from the Research Registry, comparing treatment with uorinated glucocorticoids to the natural history of untreated CHB. 30 The cohort included 47 mothers whose sera contain anti-SSA/Ro or anti-SSB/La antibodies, and their 50 offspring with CHB, in whom at least four echocardiograms were performed after in utero diagnosis. In 28 pregnancies, the mothers were treated with dexamethasone 4 -9mg/day (most received 4mg) for 4-19 weeks or betamethasone 12mg/week for > 6 weeks (Group A). On average, 1.6 weeks passed between the detection of bradyarrhythmia and the initiation of steroids. In 22 pregnancies, uorinated steroids were not given (Group B). Echocardiographic evaluation revealed pericardial effusions in 13 Group A versus 4 Group B (P < 0.06), pleural effusions in 2 Group A versus 0 Group B (P NS), ascites in 8 Group A versus 0 Group B (P < 0.02), hydrops in 8 Group A versus 0 Group B (P < 0.02), and intrauterine growth restriction in 1 Group A versus 1 Group B (P NS). Steroid therapy was most effective in the sustained resolution of pleural effusions (2/2), ascites (6/8) and hydrops (5/8) . The time to resolution was extremely variable. Oligohydramnios ensued in 8 Group A and 2 Group B (P NS). While this latter complication is certainly a concern as an adverse consequence of maternal steroid use, it is of interest that in Group A the presence or development of oligohydramnios was signi cantly associated with the maternal diagnosis of SLE (P 0.008). These ndings suggest that maternal disease might also contribute to the development of oligohydramnios.
In summary, Fesslova and colleagues seem to hit the translational research 'nail' on the head, and report a fascinating situation in which not only was the spectrum of AV nodal block discordant in a triplet gestation, but in one of the fetuses myocarditis progressed to third-degree block. For the clinician this case provides critical evidence that antibodies likely initiate a more global in ammatory process prior to irreversible brosis. It is the former that can be reversed by steroids while the latter seems to be irreversible once the programme of scarring is set into motion. Although the window of therapeutic opportunity may be limited, this case report also suggests that such an opportunity exists if we could nd the right treatment. It also reinforces the critical need for frequent fetal monitoring with the appropriate tools beginning as early as 16 weeks of gestation. From the laboratory perspective it is clear that fetal factors are important, but in addition to a genetic contribution, there is an environmental factor also at play.
